Chester County News and Community Website
NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) has announced its successful return to compliance with Nasdaq’s minimum stockholders’ equity requirements, ensuring the continuation of its listing on the Nasdaq Capital …
Traws Pharma Regains Nasdaq Compliance, Strengthening Position for 2025 Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has announced the successful completion of Phase I clinical trials for tivoxavir marboxil, an investigational one-dose treatment aimed at combating H5N1 bird flu. …
Traws Pharma Advances Bird Flu Treatment with Successful Phase I Trial Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has finalized agreements to raise up to $72.6 million to support the development of its promising bird flu treatment, Tivoxavir Marboxil. The …
Traws Pharma Secures $72.6 Million for Bird Flu Treatment Development Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has shared its latest business updates and unaudited financial results for the third quarter ending September 30, 2024. The company is advancing …
Traws Pharma Reports Q3 Financials and Updates on Clinical Advances Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has announced promising topline results from its Phase 1 study of tivoxavir marboxil, an investigational one-dose influenza treatment. Designed to inhibit the CAP-dependent …
Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has reported encouraging topline results from its Phase 1 trial of ratutrelvir, an oral inhibitor designed to combat COVID-19. The trial demonstrated favorable …
Promising Phase 1 Results for Traws Pharma’s COVID Treatment Candidate Read More NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) recently announced a pivotal shift in its board with the appointment of Luba Greenwood as Director.
Traws Pharma Welcomes Luba Greenwood Amid Strategic Board Changes Read More NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) recently concluded its 2024 Special Meeting of Stockholders with significant decisions impacting the company’s capital structure. Shareholders approved all proposals outlined in the …
Traws Pharma Announces Key Approvals and Reverse Stock Split at 2024 Special Meeting Read More NEWTOWN, PA — Traws Pharma, Inc. announced its second quarter 2024 financial results and highlighted key developments following its merger with Trawsfynydd Therapeutics. The merger, completed in April, included a …
Traws Pharma Reports Q2 Financials and Merger with Trawsfynydd Therapeutics Read More NEWTOWN, PA — Traws Pharma, Inc. has unveiled encouraging preclinical results for its COVID-19 drug, ratutrelvir, at the International Conference on Antiviral Research (ICAR2024) in Gold Coast, Australia. Ratutrelvir, also …
Traws Pharma Showcases Promising COVID-19 Drug at ICAR Conference Read More